Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

2.

Erythematous Macular Eruption in an Older Woman.

McLaughlin D, Kernohan NM, Tauro S.

JAMA Oncol. 2019 Apr 1;5(4):565-566. doi: 10.1001/jamaoncol.2018.5317. No abstract available.

PMID:
30543345
3.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

4.

The diversity of neutrophil inclusion bodies in fulminant sepsis.

Boyd K, Tauro S.

Br J Haematol. 2018 Aug;182(3):317. doi: 10.1111/bjh.15218. Epub 2018 May 24. No abstract available.

PMID:
29797395
5.

Telomere length is an independent prognostic marker in MDS but not in de novo AML.

Williams J, Heppel NH, Britt-Compton B, Grimstead JW, Jones RE, Tauro S, Bowen DT, Knapper S, Groves M, Hills RK, Pepper C, Baird DM, Fegan C.

Br J Haematol. 2017 Jul;178(2):240-249. doi: 10.1111/bjh.14666. Epub 2017 May 9.

PMID:
28486748
6.

An unusual extranodal T-cell non-Hodgkin lymphoma.

Coats JT, Mackie ADR, Kernohan NM, Ramkumar PG, McMahon LM, Goodlad JR, Tauro S.

Lancet. 2016 Sep 10;388(10049):1127-1128. doi: 10.1016/S0140-6736(16)30447-0. No abstract available.

PMID:
27628520
7.

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2016 Oct 20;128(16):2096-2097. doi: 10.1182/blood-2016-07-728766. Epub 2016 Aug 17. No abstract available.

8.

Time-dependent changes in mortality and transformation risk in MDS.

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22.

9.

The blind men and the AML elephant: can we feel the progress?

Tauro S.

Blood Cancer J. 2016 May 13;6:e424. doi: 10.1038/bcj.2016.33. Review.

10.

Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.

Mastaglio F, Bedair K, Papaemmanuil E, Groves MJ, Hyslop A, Keenan N, Hothersall EJ, Campbell PJ, Bowen DT, Tauro S.

Br J Haematol. 2016 Jul;174(2):227-34. doi: 10.1111/bjh.14042. Epub 2016 Apr 20.

PMID:
27098194
11.

Ester Prodrugs of Ketoprofen: Synthesis, Hydrolysis Kinetics and Pharmacological Evaluation.

Dhokchawle BV, Tauro SJ, Bhandari AB.

Drug Res (Stuttg). 2016 Jan;66(1):46-50. doi: 10.1055/s-0035-1548908. Epub 2015 Apr 20.

PMID:
25894087
12.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M.

Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.

PMID:
25721895
13.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE.

Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15. Erratum in: Cancer Cell. 2014 Jun 16;25(6):861. Cancer Cell. 2015 Apr 13;27(4):603-5.

14.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

15.

p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia.

Groves MJ, Johnson CE, James J, Prescott AR, Cunningham J, Haydock S, Pepper C, Fegan C, Pirrie L, Westwood NJ, Coates PJ, Ganley IG, Tauro S.

Br J Cancer. 2013 Oct 29;109(9):2434-44. doi: 10.1038/bjc.2013.601. Epub 2013 Oct 3.

16.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.

17.

Diversification and senescence of Foxp3+ regulatory T cells during experimental autoimmune encephalomyelitis.

Tauro S, Nguyen P, Li B, Geiger TL.

Eur J Immunol. 2013 May;43(5):1195-207. doi: 10.1002/eji.201242881. Epub 2013 Apr 9.

18.

Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6.

MacCallum SF, Groves MJ, James J, Murray K, Appleyard V, Prescott AR, Drbal AA, Nicolaou A, Cunningham J, Haydock S, Ganley IG, Westwood NJ, Coates PJ, Lain S, Tauro S.

Sci Rep. 2013;3:1275. doi: 10.1038/srep01275.

19.

Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.

Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C.

Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5.

PMID:
23395505
20.

Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.

Durairaj S, Keenan N, Hyslop A, Groves MJ, Bowen DT, Tauro S.

Br J Haematol. 2013 Apr;161(2):280-2. doi: 10.1111/bjh.12204. Epub 2013 Jan 7. No abstract available.

PMID:
23294041
21.

IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells.

Hasnain SZ, Tauro S, Das I, Tong H, Chen AC, Jeffery PL, McDonald V, Florin TH, McGuckin MA.

Gastroenterology. 2013 Feb;144(2):357-368.e9. doi: 10.1053/j.gastro.2012.10.043. Epub 2012 Oct 31.

PMID:
23123183
22.

Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot Study.

Groves MJ, Maccallum SF, Boylan MT, Haydock S, Cunningham J, Gelly K, Gowans D, Kerr R, Coates PJ, Tauro S.

J Cancer. 2012;3:354-61. doi: 10.7150/jca.4813. Epub 2012 Aug 24.

23.

Revised international prognostic scoring system for myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2012 Sep 20;120(12):2454-65. Epub 2012 Jun 27.

24.

Nature and nurture in Foxp3(+) regulatory T cell development, stability, and function.

Geiger TL, Tauro S.

Hum Immunol. 2012 Mar;73(3):232-9. doi: 10.1016/j.humimm.2011.12.012. Epub 2011 Dec 27. Review.

25.

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, Gallì A, Da Vià MC, Conte S, Tauro S, Keenan N, Hyslop A, Hinton J, Mudie LJ, Wainscoat JS, Futreal PA, Stratton MR, Campbell PJ, Hellström-Lindberg E, Cazzola M; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.

Blood. 2011 Dec 8;118(24):6239-46. doi: 10.1182/blood-2011-09-377275. Epub 2011 Oct 12.

26.

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

N Engl J Med. 2011 Oct 13;365(15):1384-95. doi: 10.1056/NEJMoa1103283. Epub 2011 Sep 26.

27.

Absolute SILAC-compatible expression strain allows Sumo-2 copy number determination in clinical samples.

Matic I, Jaffray EG, Oxenham SK, Groves MJ, Barratt CL, Tauro S, Stanley-Wall NR, Hay RT.

J Proteome Res. 2011 Oct 7;10(10):4869-75. doi: 10.1021/pr2004715. Epub 2011 Aug 25.

28.

Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates.

Durairaj S, Chew S, Hyslop A, Keenan N, Groves MJ, Tauro S.

Am J Hematol. 2011 May;86(5):406-10. doi: 10.1002/ajh.22001.

29.

Experimental demonstration of Generalized Phase Contrast based Gaussian beam-shaper.

Tauro S, Bañas A, Palima D, Glückstad J.

Opt Express. 2011 Apr 11;19(8):7106-11. doi: 10.1364/OE.19.007106.

PMID:
21503023
30.

Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.

Groves MJ, Sales M, Baker L, Griffiths M, Pratt N, Tauro S.

Cancer Genet. 2011 Jan;204(1):39-44. doi: 10.1016/j.cancergencyto.2010.08.017.

PMID:
21356190
31.

Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript.

Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A, Fernandes K, Tauro S, Bourdon JC.

FEBS Lett. 2010 Nov 5;584(21):4463-8. doi: 10.1016/j.febslet.2010.10.005. Epub 2010 Oct 13.

32.

Dynamic axial stabilization of counter-propagating beam-traps with feedback control.

Tauro S, Bañas A, Palima D, Glückstad J.

Opt Express. 2010 Aug 16;18(17):18217-22. doi: 10.1364/OE.18.018217.

PMID:
20721211
33.
34.

Immunohistochemical localization of cellular NFATc1 does not predict clinical responses to ciclosporin in subcutaneous panniculitis-like T-cell non-Hodgkin lymphoma.

Tauro S, Maccallum S, Groves MJ, Rojnuckarin P, Assanasen T, Feldman AL, Robson A, Marschalkó M, Kini H, Alzolibani AA, Al Robaee A, Al Shobaili HA, Alfawzan S, Goodlad JR, Kernohan N, Hummel M, Sterry W, Assaf C.

Br J Dermatol. 2010 Apr;162(4):887-9. doi: 10.1111/j.1365-2133.2009.09616.x. Epub 2010 Jan 21. No abstract available.

PMID:
20096007
35.

Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia.

Foster N, Paulsson K, Sales M, Cunningham J, Groves M, O'Connor N, Begum S, Stubbs T, McMullan DJ, Griffiths M, Pratt N, Tauro S.

Br J Haematol. 2010 Mar;148(6):938-43. doi: 10.1111/j.1365-2141.2009.08039.x. Epub 2010 Jan 11.

PMID:
20064152
36.

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N.

Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30.

37.

Chest pain and small red cells: size does matter.

Tauro S, Hutcheon S.

Lancet. 2009 Aug 1;374(9687):426. doi: 10.1016/S0140-6736(09)60936-3. No abstract available.

PMID:
19647610
38.

Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.

MacCallum S, Groves M, Brass D, Cunningham J, Sales M, Gelly K, Tauro S.

J Clin Pathol. 2009 May;62(5):468-70. doi: 10.1136/jcp.2008.061143.

PMID:
19398596
39.

The annexin-V assay reflects susceptibility to in vitro membrane damage in chronic lymphocytic leukemia and may overestimate cell death.

Groves MJ, Maccallum S, Boylan MT, Coates PJ, Tauro S.

Am J Hematol. 2009 Mar;84(3):196-7. doi: 10.1002/ajh.21347. No abstract available.

40.

Multifocal primary extranodal B-cell non-Hodgkin's lymphoma involving six extranodal sites.

Craig J, Walker K, Bayer L, Brunton J, Oliver B, Meiklejohn D, Kernohan N, Tauro S.

J Clin Pathol. 2009 Jan;62(1):89-91. doi: 10.1136/jcp.2008.060046.

PMID:
19103866
41.

Molecular and cellular mechanisms in the viral exacerbation of asthma.

Tauro S, Su YC, Thomas S, Schwarze J, Matthaei KI, Townsend D, Simson L, Tripp RA, Mahalingam S.

Microbes Infect. 2008 Jul;10(9):1014-23. doi: 10.1016/j.micinf.2008.07.037. Epub 2008 Aug 13. Review.

PMID:
18762266
42.

Unravelling the reactivity of antisymmetric stretch-excited CH4 with Cl by-product pair-correlation measurements.

Kawamata H, Tauro S, Liu K.

Phys Chem Chem Phys. 2008 Aug 14;10(30):4378-82. doi: 10.1039/b809209e. Epub 2008 Jun 24.

PMID:
18654676
43.

Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.

Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA.

Br J Haematol. 2008 Jun;142(2):318-20. doi: 10.1111/j.1365-2141.2008.07184.x. Epub 2008 May 19. No abstract available.

PMID:
18492100
44.

Sequential tyrosine kinase inhibitor therapy: sustained disease remission in Philadelphia-positive erythroleukaemia.

Craig J, Walker K, Sales M, Cunningham J, Gelly K, Pippard MJ, Tauro S.

Br J Haematol. 2008 Aug;142(4):674-5. doi: 10.1111/j.1365-2141.2008.07222.x. Epub 2008 May 15. No abstract available.

PMID:
18485048
45.

Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis.

Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ, Png CW, Crockford TL, Cornall RJ, Adams R, Kato M, Nelms KA, Hong NA, Florin TH, Goodnow CC, McGuckin MA.

PLoS Med. 2008 Mar 4;5(3):e54. doi: 10.1371/journal.pmed.0050054.

46.

AMG 531 for chronic ITP.

Tauro S.

N Engl J Med. 2007 Jan 18;356(3):307; author reply 308. No abstract available.

PMID:
17229962
47.

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S.

J Clin Oncol. 2005 Dec 20;23(36):9387-93. Epub 2005 Nov 28.

PMID:
16314618
49.

Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?

Mahalingam S, Schwarze J, Zaid A, Nissen M, Sloots T, Tauro S, Storer J, Alvarez R, Tripp RA.

Microbes Infect. 2006 Jan;8(1):285-93. Epub 2005 Aug 10. Review.

PMID:
16182587
50.

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers.

Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss PA.

J Exp Med. 2005 Aug 1;202(3):379-86.

Supplemental Content

Support Center